The Role of Monoclonal Antibodies in the Management of Leukemia.

about

The Role of Monoclonal Antibodies in the Management of Leukemia.

Item

http://www.wikidata.org/entity/Q55506612

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

The Role of Monoclonal Antibodies in the Management of Leukemia.

@en

The Role of Monoclonal Antibodies in the Management of Leukemia.

@nl

type

Item

label

The Role of Monoclonal Antibodies in the Management of Leukemia.

@en

The Role of Monoclonal Antibodies in the Management of Leukemia.

@nl

prefLabel

The Role of Monoclonal Antibodies in the Management of Leukemia.

@en

The Role of Monoclonal Antibodies in the Management of Leukemia.

@nl

P1476

The Role of Monoclonal Antibodies in the Management of Leukemia

@en

P2093

Alessandra Ferrajoli

http://www.w3.org/2001/XMLSchema#string

Ali Al-Ameri

http://www.w3.org/2001/XMLSchema#string

Aref Al-Kali

http://www.w3.org/2001/XMLSchema#string

Mohamad Cherry

http://www.w3.org/2001/XMLSchema#string

P2860

Continuous cultures of fused cells secreting antibody of predefined specificity

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia

Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.

Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.

Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group.

Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.

P304

3258-3274

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/PH3103258

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Alessandra Ferrajoli

P577

2010-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P921

leukemia

P932

4034091

http://www.w3.org/2001/XMLSchema#string